Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds

• US 7,858,756 B2
• Filed: 06/15/2007
• Issued: 12/28/2010
• Est. Priority Date: 06/15/2006
• Status: Active Grant

• Current Assignee: Bioventures, LLC
• Original Assignee: The Board of Trustees of the University of Arkansas (University of Arkansas System)
• Inventors: Henry, Ralph, Peterson, Eric, Chi, Yingni, Carroll, F. Ivy, Gunnell, Melinda, Owens, S. Michael
• Primary Examiner(s): Helms; Larry R
• Assistant Examiner(s): Sang; Hong
• Application Number:
  US11/763,948
• Publication Number:
  US 20080125579A1
• Time in Patent Office: 1,292 Days
• Field of Search: 530/387.1, 530/388.1, 424/130.1, 435/7.1
• US Class Current: 530/388.1
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.

Claims

1. An isolated monoclonal antibody that recognizes each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine, and does not substantially recognize each compound of the group consisting of (−

)amphetamine, (−

)methamphetamine, and (−

)3,4-methylenedioxymethamphetamine, wherein the antibody is generated using a immunizing agent comprising the formula

2. The isolated monoclonal antibody of claim 1, wherein the antibody has an IC₅₀ ratio calculated in reference to (+)methamphetamine of less than about 12% for each compound of the group consisting of (−

)amphetamine, (−

) methamphetamine, and (−

)3,4-methylenedioxymethamphetamine.

3. The isolated monoclonal antibody of claim 1, wherein the antibody has an IC₅₀ ratio calculated in reference to (+)methamphetamine of greater than about 25% for each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine.

4. The isolated monoclonal antibody of claim 3, wherein the antibody has an IC₅₀ ratio calculated in reference to (+)methamphetamine of less than about 12% for each compound of the group consisting of (−

)amphetamine, (−

) methamphetamine, and (−

)3,4-methylenedioxymethamphetamine.

5. The isolated monoclonal antibody of claim 1, wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:

25, and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO;

26.

6. The isolated monoclonal antibody of claim 1, wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:

19, and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO;

21.

7. The isolated monoclonal antibody of claim 1, wherein the antibody is selected from the group consisting of a murine antibody, a human antibody, a humanized antibody, a chimeric antibody, a recombinant antibody, and an antigen binding fragment of an antibody.

8. A method of treating drug use in a subject, the method comprising administering a monoclonal antibody of claim 1 to the subject, wherein the monoclonal antibody decreases the concentration of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine in the brain of the subject.

9. The method of claim 8, wherein the subject is selected from the group comprising a rodent, a non-human primate, and a human.

10. A method of treating drug use in a subject, the method comprising administering a monoclonal antibody of claim 1 to the subject, wherein the monoclonal antibody decreases the concentration of (+)amphetamine, (+)methamphetamine, or (+)3,4-methylenedioxymethamphetamine in the brain of the subject.

11. The method of claim 10, wherein the subject is selected from the group comprising a rodent, a non-human primate, and a human.

12. A method for detecting the presence of at least one compound in a sample selected from the group of compounds consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine, the assay comprising contacting the sample with a monoclonal antibody of claim 1 and detecting the association of the monoclonal antibody in the sample with at least one compound selected from the group consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine.

13. The method of claim 12, wherein the sample is a biological sample or a chemical sample.

14. The method of claim 13, wherein the biological sample is a biological fluid.

15. The method of claim 12, wherein the association is detected by a means selected from the group consisting of ELISA, immunochromatographic assay, and immunoprecipitation assay.

16. The method of claim 12, wherein the assay further comprises quantifying the amount of a compound selected from the group of compounds consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine in the sample.

17. A kit, wherein the kit comprises a monoclonal antibody that recognizes each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine, and does not substantially recognize each compound of the group consisting of (−

)amphetamine, (−

) methamphetamine, and (−

)3,4-methylenedioxymethamphetamine, wherein the antibody is generated using a immunizing agent comprising the formula